|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, September 19, 2017 ) HCC is the most common form of primary liver cancer in adults and occurs mainly in the patients with underlying liver disease and cirrhosis. The disease originates in the liver unlike the secondary liver cancers which reaches to the liver from other organs of the body. Currently only two drugs NEXAVAR and STIVARGA are approved for the treatment of the disease.
Publisher's analysts forecast the global hepatocellular carcinoma drugs market to grow at a CAGR of 3.40% during the period 2017-2021.
For more information about this report: http://www.reportsweb.com/global-hepatocellular-carcinoma-drugs-market-2017-2021 .
Covered in this report
The report covers the present scenario and the growth prospects of the global hepatocellular carcinoma drugs market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs in HCC treatment market.
The market is divided into the following segments based on geography:
-Americas
-APAC
-EMEA
Publisher's report, Global Hepatocellular Carcinoma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
-Bayer
-Eli Lilly
-Johnson and Johnson
-Pfizer
Request Sample Copy at http://www.reportsweb.com/inquiry&RW00011065931/sample .
Other prominent vendors
-Bristol-Myers Squibb
-Celgene
-F. Hoffmann-la Roche
-Gilead
-GlaxoSmithKline
-Merck
-Novartis
-Salix Pharmaceuticals
-Transgene
Market driver
-Growing cases of hepatitis B and C infections
-For a full, detailed list, view our report
Market challenge
-Stringent government regulations and trial failure in the late stage of drug development
-For a full, detailed list, view our report
Market trend
-Increase in R&D activities for liver cirrhosis medication
-For a full, detailed list, view our report
Inquire for Report at http://www.reportsweb.com/inquiry&RW00011065931/buying .
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
